Cargando…
GNS561 acts as a potent anti-fibrotic and pro-fibrolytic agent in liver fibrosis through TGF-β1 inhibition
BACKGROUND: Hepatic fibrosis is the result of chronic liver injury that can progress to cirrhosis and lead to liver failure. Nevertheless, there are no anti-fibrotic drugs licensed for human use. Here, we investigated the anti-fibrotic activity of GNS561, a new lysosomotropic molecule with high live...
Autores principales: | Bestion, Eloïne, Jilkova, Zuzana Macek, Mège, Jean-Louis, Novello, Marie, Kurma, Keerthi, Pour, Seyedeh Tayebeh Ahmad, Lalmanach, Gilles, Vanderlynden, Lise, Fizanne, Lionel, Bassissi, Firas, Rachid, Madani, Tracz, Jennifer, Boursier, Jérôme, Courcambeck, Jérôme, Serdjebi, Cindy, Ansaldi, Christelle, Decaens, Thomas, Halfon, Philippe, Brun, Sonia |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7366401/ https://www.ncbi.nlm.nih.gov/pubmed/32728410 http://dx.doi.org/10.1177/2040622320942042 |
Ejemplares similares
-
GNS561, a clinical-stage PPT1 inhibitor, is efficient against hepatocellular carcinoma via modulation of lysosomal functions
por: Brun, Sonia, et al.
Publicado: (2021) -
GNS561, a New Autophagy Inhibitor Active against Cancer Stem Cells in Hepatocellular Carcinoma and Hepatic Metastasis from Colorectal Cancer
por: Brun, Sonia, et al.
Publicado: (2021) -
GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition
por: Bestion, Eloïne, et al.
Publicado: (2022) -
Animal Models of Hepatocellular Carcinoma: The Role of Immune System and Tumor Microenvironment
por: Macek Jilkova, Zuzana, et al.
Publicado: (2019) -
Cell and Animal Models for SARS-CoV-2 Research
por: Bestion, Eloïne, et al.
Publicado: (2022)